Forward P/S Multiple: Inspira Technologies Oxy B.H.N. Ltd. (IINN)

Inspira Technologies - graphic logo of issuer IINN

Is it worth investing in Inspira Technologies Oxy (IINN), given the dependence on FDA approvals and R&D costs? This chart on GURU.Markets reflects the forward P/S ratio, with a current value of 56.30, confirming the stability of ventilator assembly despite partial electronics outsourcing. This will result in profit growth driven by the sale of consumables for blood oxygenation systems.

Inspira Technologies - IINN Market Cap to Projected Revenue (period 10/03/2025 - 05/20/2026)

Summary analytical data breakdowns for Inspira Technologies (IINN)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Fundamental company analysis:IINN (inspira-technologies.com)
Product sample of inspira-technologies.com

Inspira Technologies Oxy's monopoly on molecular blood saturation and strict FDA control determine the high value of future cash flows. The ratio of current market capitalization to projected sales allows for an assessment of the premium paid for the technological barrier, while an analysis of forward capitalization to revenue helps identify asset overheating in time to avoid buying at the peak of market optimism.

Who Inspira Technologies Oxy competes with

Price-to-Projected Revenue Ratio Dexcom CGM DXCM|Penumbra Corp (PEN) - Market Cap to Future Revenue Ratio|Novanta Inc - Forward P/S Multiple|HAE (Haemonetics Corporation) - Market Cap to Projected Revenue|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED Inc.) - Forward P/S Multiple|Pulse Corp (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward P/S Multiple picardmedical.com (PMI)|Forward P/S Multiple SRDX (surmodics.com)|Forward P/S Multiple Senseonics Holdings, Inc. SENS|NPCE - Price-to-Projected Revenue Ratio|TCMD: Price-to-Projected Revenue Ratio|SNWV (Sanuwave Health Inc) - Forward Price-to-Revenue Multiple|Projected Price to Revenue Outset Medical OM|ELMD (SmartVest) - Forward P/S Multiple|Market Cap to Future Revenue Ratio LENSAR Inc. LNSR|Price-to-Projected Revenue Ratio AVITA Medical Inc. (RCEL)|Profound Medical Corporation (PROF) - Projected Price to Revenue|Baird Medical Investment Holdings - Forward Price-to-Revenue Multiple|Forward P/S Multiple EDAP Medical EDAP|Apyx Medical Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio IceCure Medical ICCM|Pulmonx (LUNG) - Price-to-Projected Revenue Ratio|Future Price to Revenue TELA (TELA Bio Corp)|Price-to-Projected Revenue Ratio cytosorbents.com|Forward Price-to-Revenue Multiple Sensus Healthcare, Inc. (SRTS)|Forward P/S Multiple ZYXI|ECOR - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio vicarioussurgical.com RBOT|Price to Expected Revenue Ratio ICU (SeaStar Medical Holding Corp.)|IRIX: Forward Price-to-Revenue Multiple|ibs.inc - Price to Expected Revenue Ratio|XAIR: Forward P/S Multiple|Future Price to Revenue PFSA (Profusa Inc.)|Forward Price-to-Revenue Multiple SSKN|Price-to-Projected Revenue Ratio GCTK|Price-to-Projected Revenue Ratio NanoVibronix (NAOV)|Venus Concept - Market Cap to Projected Revenue|Forward P/S Multiple NUWE (Nuwellis Corp)|Forward Price to Sales AEMD|ASXC - Price-to-Projected Revenue Ratio|Projected Price to Revenue Avinger, Inc (AVGR)|BSGM: Forward P/S Multiple|Cutera (CUTR) - Forward P/S Multiple|KNW (Know Labs) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Inari Medical (NARI)|Price-to-Projected Revenue Ratio nevro.com (NVRO)|RSLS (ReShape Lifesciences, Inc.) - Forward Price to Sales|Forward P/S Multiple SILK (Silk Road Medical)